Company / Gross Profit
Acadia Pharmaceuticals Gross Profit History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$684.8M
FY2023
5-year range
$473.3M / $684.8M
FY2019-FY2023
Trend
+35.1%
vs FY2022
Sector context
#11 of 29
Health Care
What the data says
At $685M, Acadia Pharmaceuticals's gross profit ranks #11 of 29 in the Health Care sector. Gross Profit has increased for 7 consecutive years, from $14M in FY2016 to $685M in FY2023.
Based on SEC 10-K filings.
$685M in FY2023 with a 5-year CAGR of +26.5%.
Improved from $473M to $685M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +16.6%
- 5-Year CAGR
- +26.5%
- 10-Year CAGR
- -
Sector benchmark
#11 of 29 in Health CareTop 38% of 29This company $684.8M Sector average $3.5B
▼
-80.2% below sector average
Key checks
Key Insights
- Acadia Pharmaceuticals's gross profit has grown for 7 consecutive years.
- 5-year CAGR of +26.5%, indicating consistent growth.
- In FY2023, gross profit increased 35.1% year-over-year.
- Ranks #11 out of 29 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $684.8M | +35.1% |
| FY2022 | $507.1M | +7.1% |
| FY2021 | $473.3M | +9.7% |
| FY2020 | $431.5M | +31.7% |
| FY2019 | $327.7M | +55.0% |
| FY2018 | $211.4M | +82.5% |
| FY2017 | $115.8M | +712.7% |
| FY2016 | $14.3M | - |
As of FY2023 · SEC 10-K · Updated Jul 1, 2026